MAPS submitted a short letter

MAPS submitted a short letter to the Western IRB’s Executive Policy Committee, in advance of its November 19 meeting at which it will discuss its review of MAPS’ MDMA/PTSD protocol. The letter discussed MAPS’ Israeli MDMA/PTSD project, briefly reviewed US government and international treaty policies regarding research with Schedule I drugs, and reported that MAPS had submitted unpublished data to FDA about MDMA and heart valve tissue, data which the WIRB cited as partial justification for revoking approval which neither MAPS nor FDA had seen.